DarioHealth (NASDAQ:DRIO) Stock Passes Below 200 Day Moving Average – What’s Next?

DarioHealth Corp. (NASDAQ:DRIO) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.71 and traded as low as $7.00. DarioHealth shares last traded at $7.06, with a volume of 5,075 shares.

Analyst Ratings Changes

DRIO has been the subject of several research analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $10.00 target price on shares of DarioHealth in a research note on Thursday, May 14th. TD Cowen reiterated a “hold” rating and set a $11.00 target price on shares of DarioHealth in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.50.

DarioHealth Trading Down 1.9%

The stock has a market capitalization of $51.61 million, a price-to-earnings ratio of -0.80 and a beta of 1.11. The company’s 50 day moving average is $7.62 and its 200 day moving average is $9.71. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.62 and a current ratio of 3.07.

Hedge Funds Weigh In On DarioHealth

Hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in shares of DarioHealth in the 4th quarter valued at $35,000. Geode Capital Management LLC raised its stake in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after buying an additional 43,513 shares in the last quarter. Institutional investors and hedge funds own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.